It depends on the standard you follow. As of September 2026, SI-BONE, Inc. (SIBN) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 3.97% / 30% · (Cash+Inv) / Mkt Cap (36m) 16.3% / 30% · Interest income / Revenue 2.42% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 3.97% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 16.3% / 33% · Receivables / Mkt Cap (36m) 3.50% / 49% · Interest income / Revenue 2.42% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 3.97% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 16.3% / 33.33% · Receivables / Mkt Cap (24m) 3.50% / 33.33% · Interest income / Revenue 2.42% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 5.20% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 59.3% / 33.33% · Receivables / Avg Assets (4Q) 12.5% / 33.33% · Interest income / Revenue 2.42% / 5% | Fail |
| FTSE | Debt / Total Assets 13.9% / 33.33% · (Cash+ST Inv) / Total Assets 57.0% / 33.33% · (Cash+Recv) / Total Assets 69.2% / 33.33% · Interest income / Revenue 2.42% / 5% | Fail |
It depends on the standard you follow. As of September 2026, SI-BONE, Inc. (SIBN) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. SI-BONE, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 2.42% of each dividend: SI-BONE, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
SI-BONE, Inc. (NASDAQ: SIBN) is a Healthcare company (Medical - Devices) with a market capitalization of $1.0B. The Maz Rating grades it against the other companies in its sector.
SI-BONE, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $23.16, SI-BONE, Inc. trades at 4.7x sales and 5.6x book value. Over the last twelve months it generated about $221M of revenue and a net loss of $14M. It runs a gross margin of 79.4%, an operating margin of -7.6% and a net margin of -6.2%. It shows return on equity of -7.6%, return on invested capital of -7.3% and a free cash flow yield of -0.4%. On the balance sheet: a debt-to-equity ratio of 0.23 and a current ratio of 7.58. Over the past 52 weeks the share price ranged from $11.48 to $25.92, with a beta of 0.64.
SI-BONE, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 10 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.